Literature DB >> 19259616

Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report.

Paola Gaviani1, A Silvani, E Corsini, A Erbetta, A Salmaggi.   

Abstract

Neoplastic meningitis from breast cancer often leads to a progressive neurologic deterioration followed by fatal outcome. The therapy is based on the administration of high dose systemic chemotherapy with drugs able to pass through the blood-brain barrier, such as methotrexate (MTX) and cytarabine, cranial or craniospinal irradiation, and intrathecal (IT) administration of MTX and/or cytarabine. However, these approaches only have modest efficacy and are associated with side effects for the patients. A depot formulation of liposomal cytarabine (DepoCyte) has proven to be useful in clinical trials. We describe the case of a woman with a diagnosis of leptomeningeal carcinomatosis from breast carcinoma who presented cerebrospinal fluid normalization and prolonged complete MRI response to intrathecal chemotherapy with liposomal cytarabine (DepoCyte).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259616     DOI: 10.1007/s10072-009-0044-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Diagnosis and outcome measures in trials for neoplastic meningitis: a review of the literature and clinical experience.

Authors:  M J Glantz; B C Walters
Journal:  Neurosurg Focus       Date:  1998-06-15       Impact factor: 4.047

2.  [Experience with the intrathecal use of liposomal cytarabine at the Besta Institute].

Authors:  Antonio Silvani
Journal:  Tumori       Date:  2007 May-Jun       Impact factor: 2.098

Review 3.  Leptomeningeal carcinomatosis.

Authors:  S A Grossman; M J Krabak
Journal:  Cancer Treat Rev       Date:  1999-04       Impact factor: 12.111

Review 4.  Neoplastic meningitis.

Authors:  Marc C Chamberlain
Journal:  Neurologist       Date:  2006-07       Impact factor: 1.398

5.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

Authors:  M J Glantz; K A Jaeckle; M C Chamberlain; S Phuphanich; L Recht; L J Swinnen; B Maria; S LaFollette; G B Schumann; B F Cole; S B Howell
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

Review 6.  Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.

Authors:  Antonio Rueda Domínguez; David Olmos Hidalgo; Ruth Viciana Garrido; Esperanza Torres Sánchez
Journal:  Clin Transl Oncol       Date:  2005-07       Impact factor: 3.405

Review 7.  Management of leptomeningeal malignancy.

Authors:  George Pentheroudakis; Nicholas Pavlidis
Journal:  Expert Opin Pharmacother       Date:  2005-06       Impact factor: 3.889

8.  Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.

Authors:  F J Esteva; L T Soh; F A Holmes; W Plunkett; C A Meyers; A D Forman; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

9.  An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.

Authors:  Kurt A Jaeckle; Tracy Batchelor; Steven J O'Day; Surasak Phuphanich; Pamela New; Glenn Lesser; Allen Cohn; Mark Gilbert; Robert Aiken; Deborah Heros; Lisa Rogers; Eric Wong; Dorcas Fulton; John C Gutheil; Said Baidas; Julia M Kennedy; Warren Mason; Paul Moots; Christy Russell; Lode J Swinnen; Stephen B Howell
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

Review 10.  Neoplastic meningitis.

Authors:  L Kim; M J Glantz
Journal:  Curr Treat Options Oncol       Date:  2001-12
  10 in total
  7 in total

1.  Meningeal carcinomatosis in breast cancer: prognostic factors and outcome.

Authors:  Carla Rameri Alexandre Silva de Azevedo; Marcelo Rocha Sousa Cruz; Ludmilla Thomé Domingos Chinen; Stela Verzinhasse Peres; Marcos Aurélio Peterlevitz; Artur Eugênio de Azevedo Pereira; Marcello Ferretti Fanelli; Daniel Luiz Gimenes
Journal:  J Neurooncol       Date:  2011-01-14       Impact factor: 4.130

Review 2.  Biology and therapy of neoplastic meningitis.

Authors:  Aaron G Mammoser; Morris D Groves
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

3.  Intrathecal gene therapy for treatment of leptomeningeal carcinomatosis.

Authors:  John D Heiss; Sara Taha; Edward H Oldfield; Zvi Ram
Journal:  J Neurooncol       Date:  2010-11-26       Impact factor: 4.130

4.  Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.

Authors:  Hideya Onishi; Takashi Morisaki; Yuji Nakafusa; Yutaka Nakashima; Kazunori Yokohata; Mitsuo Katano
Journal:  Int J Clin Oncol       Date:  2011-02-15       Impact factor: 3.402

Review 5.  Optic neuritis as isolated manifestation of leptomeningeal carcinomatosis: a case report and systematic review of ocular manifestations of neoplastic meningitis.

Authors:  Silvia Lanfranconi; Paola Basilico; Ilaria Trezzi; Linda Borellini; Giulia Franco; Vittorio Civelli; Francesco Pallotti; Nereo Bresolin; Pierluigi Baron
Journal:  Neurol Res Int       Date:  2013-10-07

Review 6.  Leptomeningeal metastasis in breast cancer - a systematic review.

Authors:  Brian J Scott; Nancy A Oberheim-Bush; Santosh Kesari
Journal:  Oncotarget       Date:  2016-01-26

7.  Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.

Authors:  Francisco José Valdivia García; Natalia Palazón Carrión; Luis de la Cruz-Merino
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.